Many forms of cutaneous and mucosal allergy are mediated for a large part by mast cells ; they play a central role in asthma , eczema , itch (from various causes) and allergic rhinitis and allergic conjunctivitis . Antihistamine drugs act by blocking the action of histamine on nerve endings. Cromoglicate -based drugs (sodium cromoglicate, nedocromil) block a calcium channel essential for mast cell degranulation, stabilizing the cell and preventing release of histamine and related mediators. Leukotriene antagonists (such as montelukast and zafirlukast ) block the action of leukotriene mediators, and are being used increasingly in allergic diseases.
Mississippi Aphasia Screening Test (MAST) was developed as a brief,
repeatable screening measure for individuals with severely impaired
communication/language skills. Such a brief measure may be advantageous
for individuals with severe language impairments who may be frustrated
and stressed during lengthy testing sessions. The MAST was designed
to be used for serial assessments to detect changes in language
abilities over time. The MAST was initially developed by a team
of neuropsychologists, physiatrists, and speech-language pathologists.
The current form has nine subtests that range from 1 to 10 items
per subscale. The MAST can be administered in 5 to 15 minutes. Finally,
it has been utilized with a wide variety of patient populations
including traumatic brain injury, stroke, epilepsy, anoxia, dementia,
and various encephalopathies.
regarding the MAST was contributed by Methodist
Rehabilitation Center . Please contact Risa Nakase-Thompson,
Nakase-Thompson, R. (2004). The Mississippis Aphasia Screening Test. The Center for Outcome Measurement in Brain Injury. http:///combi/mast ( accessed ). Copyright © 1998-2012 Home | Background | Scales | Survey | Newsletter